Document is current
Any future updates will be listed below
-
Authors
Kawai, Taketo https://orcid.org/0000-0002-7279-2874
Kiyonaga, Fumiko
Shibata, Hirotaka
Tanaka, Yusuke
Saito, Atsushi
-
Funding
Funding for this research was provided by:
Astellas Pharma Inc
Pfizer Inc
- License Information
-
More Information
Article History
Received: 28 August 2025
Accepted: 6 November 2025
First Online: 29 November 2025
Declarations
:
: Taketo Kawai reports receiving research funding and consulting fees from Astellas Pharma, and honoraria from Astellas Pharma, Merck Biopharma, and Sanofi. Fumiko Kiyonaga, Hirotaka Shibata, Yusuke Tanaka, and Atsushi Saito are employees of Astellas Pharma Inc, the sponsor of this study.
: The study protocol was reviewed and approved by the Medical Affairs Protocol Review Committee of Astellas Pharma Inc. This study was conducted in accordance with the protocol, International Council for Harmonisation Guidelines, applicable regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. As the dataset was anonymized for secondary use, the requirements for ethical approval and informed consent did not apply to this study, as specified by Japan’s Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Data were purchased from MDV after obtaining the necessary permissions.
